Zealand Pharma Launches Phase III Petrelintide Obesity Trial with Roche

Danish biotech Zealand Pharma has launched a Phase III trial of petrelintide, an obesity drug candidate developed with Roche, testing it in 7,000 patients, Investir reported.

The company, which has built its reputation on peptide chemistry, has assembled a dense research pipeline in obesity. Two pharmaceutical majors, Roche and Boehringer Ingelheim, have signed partnership deals with it, Investir reported.

The stakes are now concrete. Roche can pay Zealand Pharma up to 5.3 billion dollars under the agreement covering petrelintide, the amylin analogue now entering Phase III testing.

  • Petrelintide works through a different hormone pathway than the GLP-1 drugs: it mimics amylin, a peptide hormone that promotes satiety — the feeling of fullness — through its action on the brain.
  • Its main selling point is side-effect tolerance. In earlier trials, only 1.9 percent of participants stopped taking it because of gastrointestinal side effects, versus 1.7 percent on placebo, according to Investir’s report.
  • The drug may be less effective than competitors, but if patients can take it without vomiting, the trade-off could be important.

Petrelintide takes the opposite bet. As an amylin analogue, it engages a satiety pathway alongside, rather than instead of, GLP-1 — and the Phase III program now underway with Roche will test whether that translates into fewer patients quitting. The 7,000-patient study is the scale being used.

That earlier signal is the number worth holding onto. In prior testing, gastrointestinal adverse events led just 1.9 percent of participants to withdraw, Investir reported — a level close to the 1.7 percent seen with placebo. At maximum doses, the report noted, patients did not experience vomiting.

The table reflects the one head-to-head figure the reporting establishes.

The petrelintide development program is funded through the Zealand Pharma–Roche collaboration, under which the Swiss major can pay up to 5.3 billion dollars, Investir reported. A second partnership with Boehringer Ingelheim covers Zealand’s obesity approach.

Petrelintide is an investigational drug. It is not approved and it is not available outside clinical trials.

Patients currently taking weight-loss medications should not change or stop treatment based on pipeline news. Anyone experiencing symptoms on an existing obesity therapy should contact their prescribing physician promptly.

Decisions about obesity pharmacotherapy belong with a treating clinician.

The 7,000-patient Phase III program is the central study. If it succeeds, amylin analogues could take a seat beside GLP-1 agonists in obesity care — and Zealand Pharma’s dual-partnership strategy, with Roche and Boehringer Ingelheim each holding a piece of the portfolio, is the wager that they will.

  • Investir — original reporting on Zealand Pharma’s obesity pipeline, the petrelintide Phase III launch, and the Roche collaboration terms.
  • Zealand Pharma / Roche collaboration disclosures as reported by Investir.

Medical disclaimer: This article is journalistic reporting and not medical advice. Petrelintide is investigational and not approved for use. Consult a qualified physician about any obesity treatment.

Photo of author

Health Desk

Health Desk at Archyde.

Andrej Stojakovic Leads Illinois To 99-78 Win Over Duke

TOMORROW X TOGETHER Releases Eighth Consecutive Million-Selling Album